- Home
- ADV vs SLN Comparison
ADV vs SLN Comparison
Compare ADV & SLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ADV | SLN |
|---|---|---|
| Founded | 1987 | 1994 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 293.0M | 318.4M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | ADV | SLN |
|---|---|---|
| Price | $0.89 | $6.14 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 6 |
| Target Price | $2.00 | ★ $39.67 |
| AVG Volume (30 Days) | ★ 1.1M | 309.7K |
| Earning Date | 11-06-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $3,502,796,000.00 | $25,830,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $0.96 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 40.39 |
| 52 Week Low | $0.80 | $1.97 |
| 52 Week High | $3.07 | $8.08 |
Technical Indicators
Market Signals| Indicator | ADV | SLN |
|---|---|---|
| Relative Strength Index (RSI) | 41.93 | 44.28 |
| Support Level | $0.80 | $6.11 |
| Resistance Level | $0.94 | $6.59 |
| Average True Range (ATR) | 0.07 | 0.45 |
| MACD | 0.02 | -0.03 |
| Stochastic Oscillator | 45.42 | 12.87 |
Price Performance
Historical ComparisonAbout ADV Advantage Solutions Inc.
Advantage Solutions Inc is a omnichannel retail solutions agency in North America, uniquely positioned at the intersection of consumer-packaged goods (CPG) brands and retailers.
About SLN Silence Therapeutics Plc American Depository Share
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.